NZ758836A - Lipo-glycopeptide cleavable derivatives and uses thereof - Google Patents

Lipo-glycopeptide cleavable derivatives and uses thereof

Info

Publication number
NZ758836A
NZ758836A NZ758836A NZ75883618A NZ758836A NZ 758836 A NZ758836 A NZ 758836A NZ 758836 A NZ758836 A NZ 758836A NZ 75883618 A NZ75883618 A NZ 75883618A NZ 758836 A NZ758836 A NZ 758836A
Authority
NZ
New Zealand
Prior art keywords
glycopeptide
lipo
derivatives
lgpc
bacterial infections
Prior art date
Application number
NZ758836A
Other languages
English (en)
Inventor
Ryan Heckler
Donna Konicek
Adam Plaunt
Vladimir Malinin
Walter Perkins
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of NZ758836A publication Critical patent/NZ758836A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ758836A 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof NZ758836A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762509378P 2017-05-22 2017-05-22
US201762518280P 2017-06-12 2017-06-12
US201762560413P 2017-09-19 2017-09-19
PCT/US2018/033963 WO2018217808A1 (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof

Publications (1)

Publication Number Publication Date
NZ758836A true NZ758836A (en) 2025-11-28

Family

ID=64395938

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ758836A NZ758836A (en) 2017-05-22 2018-05-22 Lipo-glycopeptide cleavable derivatives and uses thereof
NZ758839A NZ758839A (en) 2017-05-22 2018-05-22 Glycopeptide derivative compounds and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ758839A NZ758839A (en) 2017-05-22 2018-05-22 Glycopeptide derivative compounds and uses thereof

Country Status (11)

Country Link
US (3) US11071769B2 (cg-RX-API-DMAC7.html)
EP (2) EP3630154A4 (cg-RX-API-DMAC7.html)
JP (2) JP7165146B2 (cg-RX-API-DMAC7.html)
KR (2) KR102661786B1 (cg-RX-API-DMAC7.html)
CN (2) CN110996984A (cg-RX-API-DMAC7.html)
AU (2) AU2018271873B2 (cg-RX-API-DMAC7.html)
BR (2) BR112019024549A2 (cg-RX-API-DMAC7.html)
GB (2) GB2577420B (cg-RX-API-DMAC7.html)
IL (2) IL270686B (cg-RX-API-DMAC7.html)
NZ (2) NZ758836A (cg-RX-API-DMAC7.html)
WO (2) WO2018217800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
KR102661786B1 (ko) 2017-05-22 2024-04-26 인스메드 인코포레이티드 글리코펩티드 유도체 화합물 및 이의 용도
NL2023883B1 (en) * 2019-09-24 2021-04-26 Univ Leiden Antibiotic compounds
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023094994A1 (en) * 2021-11-24 2023-06-01 Cumberland Pharmaceuticals Inc Methods for the prevention or treatment of anthrax infection

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639433A (en) 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
PT86457B (pt) * 1986-12-30 1990-11-20 Smithkline Beecham Corp Processo para a preparacao de glicopeptidos glicosilados e de composicoes que os contem
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998029141A1 (en) 1996-12-31 1998-07-09 Inhale Therapeutic Systems, Inc. Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
JP2001517692A (ja) 1997-09-29 2001-10-09 インヘール セラピューティック システムズ， インコーポレイテッド ネブライザにおける使用のための安定化調製物
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6518242B1 (en) * 1998-02-20 2003-02-11 Theravance, Inc. Derivatives of glycopeptide antibacterial agents
CA2319495A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
UA73924C2 (en) 1998-10-09 2005-10-17 Nektar Therapeutics Device for delivering active agent formulation to lungs of human patient
PL198311B1 (pl) 1998-12-23 2008-06-30 Theravance Związki glikopeptydowe, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie
DE60041610D1 (de) 1999-05-28 2009-04-02 Nektar Therapeutics Gerät zum Abgeben von abgemessenen Mengen von Medikamente beinhaltendem Aerosol
US6606992B1 (en) 1999-06-30 2003-08-19 Nektar Therapeutics Systems and methods for aerosolizing pharmaceutical formulations
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001057071A2 (en) 2000-02-04 2001-08-09 Advanced Medicine, Inc. Glycopeptide derivatives having antibiotic activity
AU3818001A (en) 2000-02-11 2001-08-20 Lilly Co Eli Selective n-acylation of a82846 glycopeptide analogs
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
WO2004044222A2 (en) * 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
US7521418B2 (en) * 2003-05-27 2009-04-21 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
US20070185015A1 (en) * 2005-02-28 2007-08-09 Chiron Corporation and North China Pharmaceutical Corporation Semi-synthetic desmethyl-vancomycin-based glycopeptides with antibiotic activity
US7632918B2 (en) * 2005-02-28 2009-12-15 Novartis Vaccines And Diagnostics, Inc. Semi-synthetic glycopeptides with antibiotic activity
BRPI0817311A2 (pt) * 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
JP5855829B2 (ja) * 2007-10-23 2016-02-09 インスメッド， インコーポレイテッド リポソーム化バンコマイシン製剤
WO2009085562A1 (en) * 2007-12-26 2009-07-09 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
AU2010229721A1 (en) * 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
PL2424559T3 (pl) * 2009-04-28 2024-07-29 Melinta Therapeutics, Llc Sposoby leczenia zakażeń bakteryjnych z zastosowaniem orytawancyny
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
BR112013029803B1 (pt) * 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
US9879049B2 (en) 2011-08-05 2018-01-30 The Scripps Research Institute Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains
HRP20220158T1 (hr) * 2012-05-21 2022-04-15 Insmed Incorporated Sustavi za liječenje plućnih infekcija
CA2891487A1 (en) * 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
GB201402267D0 (en) * 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
US10577395B2 (en) 2014-07-10 2020-03-03 The Scripps Research Institute N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin
CN107325159A (zh) 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
WO2018008197A1 (ja) 2016-07-07 2018-01-11 日東電工株式会社 反射層および蛍光体層付光半導体素子
CA3042039C (en) 2016-10-31 2023-09-26 The Scripps Research Institute Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability
KR102661786B1 (ko) * 2017-05-22 2024-04-26 인스메드 인코포레이티드 글리코펩티드 유도체 화합물 및 이의 용도

Also Published As

Publication number Publication date
BR112019024549A2 (pt) 2020-06-09
EP3630154A1 (en) 2020-04-08
GB2577419B (en) 2022-08-17
US20220133843A1 (en) 2022-05-05
EP3630154A4 (en) 2021-03-10
KR102661790B1 (ko) 2024-04-26
GB201917675D0 (en) 2020-01-15
KR102661786B1 (ko) 2024-04-26
NZ758839A (en) 2025-08-29
GB201917677D0 (en) 2020-01-15
KR20200026803A (ko) 2020-03-11
IL270685A (cg-RX-API-DMAC7.html) 2019-12-31
CN110891590B (zh) 2023-07-18
IL270685B (en) 2022-09-01
CA3062567A1 (en) 2018-11-29
US20200368312A1 (en) 2020-11-26
IL270686B (en) 2022-09-01
AU2018273887A1 (en) 2019-11-28
EP3634464A4 (en) 2021-04-07
JP2020520986A (ja) 2020-07-16
WO2018217808A1 (en) 2018-11-29
IL270686A (cg-RX-API-DMAC7.html) 2019-12-31
AU2018271873B2 (en) 2023-11-02
CN110996984A (zh) 2020-04-10
WO2018217800A1 (en) 2018-11-29
GB2577420A (en) 2020-03-25
CN110891590A (zh) 2020-03-17
EP3634464A1 (en) 2020-04-15
JP7210476B2 (ja) 2023-01-23
CA3062570A1 (en) 2018-11-29
US11071769B2 (en) 2021-07-27
AU2018273887B2 (en) 2022-09-08
AU2018271873A1 (en) 2019-11-28
JP2020520987A (ja) 2020-07-16
GB2577420B (en) 2022-07-06
BR112019024472A2 (pt) 2020-06-16
US11857597B2 (en) 2024-01-02
US20200155640A1 (en) 2020-05-21
JP7165146B2 (ja) 2022-11-02
GB2577419A (en) 2020-03-25
KR20200027922A (ko) 2020-03-13

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
NZ758836A (en) Lipo-glycopeptide cleavable derivatives and uses thereof
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
EA202090775A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
MX2024008464A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
MX389672B (es) Inhibidores de ssao de aminopirimidina
MX341395B (es) Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc.
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX2018009633A (es) Inhibidor de indoleamina-2,3-dioxigenasa (ido).
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
CY1123892T1 (el) Κρυσταλλικες μορφες του 6-((6,7-διμεθοξυκιναζολιν-4-υλο)οξυ)-ν,2-διμεθυλοβενζοφουρανο-3-καρβοξαμιδιου
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).